OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001785345

Landos Biopharma, Inc.

Landos Biopharma, Inc. (CIK 0001785345, EIN 81-5085535) reported revenue of $18 million ($18,000,000) for FY2021 (2021-01-01 to 2021-12-31) and net income of -$21.94 million (-$21,935,000) for FY2023 (2023-01-01 to 2023-12-31), as filed in its 10-K filed 2023-03-23 (accession 0000950170-23-009334) and its 10-K filed 2024-03-21 (accession 0000950170-24-034438).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001785345
EIN81-5085535
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer category<br>Emerging growth company
Entity typeoperating
Olympus entity IDorg_0qs6vg7p4k0ycawrqnqsxkc15f
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$18,000,000FY20212021-01-01 to 2021-12-3110-K2023-03-230000950170-23-009334RevenueFromContractWithCustomerIncludingAssessedTax
Net income-$21,935,000FY20232023-01-01 to 2023-12-3110-K2024-03-210000950170-24-034438NetIncomeLoss
Total assets$38,040,000FY2023as of 2023-12-3110-K2024-03-210000950170-24-034438Assets
Total liabilities$6,249,000FY2023as of 2023-12-3110-K2024-03-210000950170-24-034438Liabilities
Stockholders' equity$31,791,000FY2023as of 2023-12-3110-K2024-03-210000950170-24-034438StockholdersEquity
Operating cash flow-$20,477,000FY20232023-01-01 to 2023-12-3110-K2024-03-210000950170-24-034438NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$3.5 per shareFY20232023-01-01 to 2023-12-3110-K2024-03-210000950170-24-034438EarningsPerShareDiluted
Shares outstanding3,116,729 sharesFY2023as of 2024-03-1510-K2024-03-210000950170-24-034438EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2014-2023, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20212021-01-01 to 2021-12-31$18,000,00010-K2023-03-230000950170-23-009334
Net incomeFY20232023-01-01 to 2023-12-31-$21,935,00010-K2024-03-210000950170-24-034438
Net incomeFY20222022-01-01 to 2022-12-31-$39,276,00010-K2024-03-210000950170-24-034438
Net incomeFY20212021-01-01 to 2021-12-31-$38,422,00010-K2023-03-230000950170-23-009334

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2024-05-092024-03-310000950170-24-056311labp-20240331.htm
10-K/A2024-04-162023-12-310001193125-24-097023d816715d10ka.htm
10-K2024-03-212023-12-310000950170-24-034438labp-20231231.htm
10-Q2023-11-092023-09-300000950170-23-061560labp-20230930.htm
10-Q2023-08-092023-06-300000950170-23-040165labp-20230630.htm
10-Q2023-05-122023-03-310000950170-23-021517labp-20230331.htm
10-K2023-03-232022-12-310000950170-23-009334labp-20221231.htm
10-Q2022-11-102022-09-300000950170-22-024194labp-20220930.htm
10-Q2022-08-112022-06-300000950170-22-016673labp-20220630.htm
10-Q2022-05-122022-03-310000950170-22-009712labp-20220331.htm
10-K2022-03-242021-12-310000950170-22-004559labp-20211231.htm
10-Q2021-11-152021-09-300000950170-21-004599labp-20210930.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001785345published by the sourcedata.sec.gov/submissions/CIK0001785345.json2026-10-21
Employer Identification Number (EIN) · US-EIN81-5085535published by the sourcedata.sec.gov/submissions/CIK0001785345.json2026-10-21

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001785345.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001785345.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001785345" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001785345/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001785345/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1785345"}

On SEC EDGAR

About this data